Reporting owner · CIK 0001856587

Ambrose Kristen

Visual SEC Form 4 history across 1 companies, 11 transactions and 7 filings.

SVP, CAOSVP & Chief Accounting OfficerVERTEX PHARMACEUTICALS INC / MA
Open-market mix
Latest filingSep 01, 2026, 08:39 PM
Filings7Form 4 records
Buying$00 purchases
Selling$1.4M3 sales
Net value−$1.4MBuys minus sells
Companies11 securities
Most recentAug 28, 2026grant

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-53Feb 25Aug 26

Net value flow

Buys minus sells

Feb 25
−$1.4M
Aug 26
$0

Transaction texture

Ownership and ticket size

Average P/S size$454.4K
Median P/S size$425.2K
Direct11
Indirect0
Aug 28, 2026grant

Filing-only signals

Deterministic matches in this insider's history

Cluster Sellingpattern2Direct Ownershipfiling-context11Large Holdings Increaseholdings2Repeat Sellerpattern210b5-1 Detectedfiling-context6

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at VERTEX PHARMACEUTICALS INC / MA on Feb 25, 2025 valued at $425,160.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at VERTEX PHARMACEUTICALS INC / MA on Feb 25, 2025 valued at $425,160.

Review SEC filing

Associated companies

Visual map of known reporting history

VRTXVERTEX PHARMACEUTICALS INC / MA11 transactions · latest Sep 01, 2026, 08:39 PM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
VRTXAmbrose Kristen
SVPCAO
grant5.00k$0A
Direct Ownership Large Holdings Increase
0.0%09/0108/28
VRTXAmbrose Kristen
SVPCAO
withholding1.24k-$59.5MF
Direct Ownership
—02/28/202502/26/2025
VRTXAmbrose Kristen
SVPCAO
sale10b5-1884-$42.5MS
Cluster Selling Direct Ownership Repeat Seller+1
—02/26/202502/25/2025
VRTXAmbrose Kristen
SVPCAO
withholding10b5-1828-$40.0MF
Direct Ownership 10b5-1 Detected
—02/26/202502/24/2025
VRTXAmbrose Kristen
SVPCAO
sale10b5-1671-$30.5MS
Cluster Selling Direct Ownership Repeat Seller+1
—02/19/202502/18/2025
VRTXAmbrose Kristen
SVPCAO
withholding10b5-1564-$26.1MF
Direct Ownership 10b5-1 Detected
—02/19/202502/14/2025
VRTXAmbrose Kristen
SVPCAO
grant2.08k$0A
Direct Ownership
—02/14/202502/12/2025
VRTXAmbrose Kristen
SVPCAO
sale10b5-11.37k-$63.2MS
Direct Ownership 10b5-1 Detected
—02/12/202502/11/2025
VRTXAmbrose Kristen
SVPCAO
withholding10b5-1591-$27.6MF
Direct Ownership 10b5-1 Detected
—02/12/202502/10/2025
VRTXAmbrose Kristen
SVPCAO
grant1.85k$0A
Direct Ownership
—02/06/202502/04/2025

Ambrose Kristen Insider Activity FAQ

SEC Form 4 context

Who is Ambrose Kristen?

Ambrose Kristen is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001856587.

Which companies has Ambrose Kristen reported transactions for?

VERTEX PHARMACEUTICALS INC / MA

When was Ambrose Kristen's latest insider buy?

No open-market insider purchase is available for this period.

When was Ambrose Kristen's latest insider sale?

sale at VERTEX PHARMACEUTICALS INC / MA on Feb 25, 2025 valued at $425,160.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.